Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.

Blood - 1 Dec 2005

Cammenga Jörg, Horn Stefan, Bergholz Ulla, Sommer Gunhild, Besmer Peter, Fiedler Walter, Stocking Carol

Abstract excerpt

Multiple genetic alterations are required to induce acute myelogenous leukemia (AML). Mutations in the extracellular domain of the KIT receptor are almost exclusively found in patients with AML carrying translocations or inversions affecting members of the core binding factor (CBF) gene family and correlate with a high risk of relapse. We demonstrate that these complex insertion and deletion mutations lead to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Core Binding Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myeloid, Acute

Share to Mutagenesis, Site-Directed

Share to Piperazines

Share to Pyrimidines

Share to Stem Cell Factor

Source

Identifiers

PMID: 16081693
DOI: 10.1182/blood-2005-02-0583

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.PMID 16081693Read ↗

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.Semantic proximity Read ↗

Complementing mutations in core binding factor leukemias: from mouse models to clinical applications.Semantic proximity Read ↗

Core binding factor acute myeloid leukaemia and c-KIT mutations.Semantic proximity Read ↗

The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia.Semantic proximity Read ↗

Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases.Semantic proximity Read ↗

KIT mutations confer a distinct gene expression signature in core binding factor leukaemia.Semantic proximity Read ↗

Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.Semantic proximity Read ↗

C-KIT signaling in cancer treatment.Semantic proximity Read ↗

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.Semantic proximity Read ↗

Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.Semantic proximity Read ↗

The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.Semantic proximity Read ↗

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.